

Curriculum vitae

Mattia D'Agostino

Current affiliation: Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy

Education

2008→University enrollment at Vita-Salute San Raffaele university, Milan, Italy

2011→Internship at Unit of Internal Medicine and Immunology directed by professor Maria Grazia Sabbadini, IRCCS Ospedale San Raffaele, Milan, Italy

2012→Internship at Hematology and Bone Marrow Transplantation Unit directed by doctor Fabio Ciceri, San Raffaele Scientific Institute, Milan, Italy.

2012-2014→Internship at Experimental Hematology Unit directed by doctor Chiara Bonini, Division of Immunology, Transplantation and Infectious Diseases, Program in Immunology and Bio-Immunotherapy of Cancer (PIBIC), San Raffaele Scientific Institute

2014→Doctor of Medicine at Vita-Salute San Raffaele university, Milan, Italy with the thesis project "Long term follow-up of patients treated with haploidentical Hematopoietic Stem Cell Transplantation and Suicide Gene Therapy reveals a wide and functional immune repertoire and long-term persistence of genetically modified Memory T Lymphocytes" (Doctoral advisor Professor Claudio Bordignon and Doctor Chiara Bonini).

2015→Residency at Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy

2019→6 months fellowship at Massachusetts General Hospital (Boston, MA, Harvard medical school affiliate) under the mentorship of professor Noopur Raje.

Publications

- Tracking genetically engineered lymphocytes long-term reveals the dynamics of T cell immunological memory, *Science Translational Medicine*, 2015 Dec 9;7(317):317ra198. doi: 10.1126/scitranslmed.aac8265.
- Moving Toward a Tailored Therapy in Multiple Myeloma. *J Oncol Pract.* 2016 Apr;12(4):293-4. doi: 10.1200/JOP.2016.011627 (First name)
- Plasma cell leukemia: update on biology and therapy. *Leuk Lymphoma.* 2017 Jul;58(7):1538-1547. doi: 10.1080/10428194.2016.1250263. Epub 2016 Nov 6. (First name)

- Novel investigational drugs active as single agents in multiple myeloma. *Expert Opin Investig Drugs*. 2017 Jun;26(6):699-711. doi: 10.1080/13543784.2017.1324571. Epub 2017 May 8. (First name)
- Immuno-oncologic approaches: CAR-T cells and Checkpoint inhibitors. *Clin Lymphoma Myeloma Leuk*. 2017 Aug;17(8):471-478. doi: 10.1016/j.clml.2017.06.014. Epub 2017 Jun 17.
- Novel immunotherapies for Multiple Myeloma. *Curr Hematol Malig Rep*. 2017 Aug 18. doi: 10.1007/s11899-017-0397-7. (First name)
- Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma. *Leukemia* 2017. doi:10.1038/leu.2017.327
- Clinical and Pharmacologic Features of Monoclonal Antibodies and Checkpoint Blockade Therapy in Multiple Myeloma. *Curr Med Chem*. 2018 May 13. doi: 10.2174 /0929867325666 1805141 14806. (First name)
- Gentle yet effective combination therapy with novel agents in elderly multiple myeloma patients. *Br J Haematol*. 2018 Jul;182(2):165-167. doi: 10.1111/bjh.15260. Epub 2018 May 6.
- Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). *Leukemia*. 2018 Apr 25. doi: 10.1038/s41375-018-0142-9.
- Determining treatment intensity in elderly patients with multiple myeloma. *Expert Rev Anticancer Ther*. 2018 Sep;18(9):917-930. doi: 10.1080/14737140.2018.1496823. (First name)
- Continuous therapy in standard- and high-risk newly-diagnosed multiple T myeloma: A pooled analysis of 2 phase III trials. *Critical Reviews in Oncology / Hematology* 132 (2018) 9–16 (First name)
- CD38 as an immunotherapeutic target in multiple myeloma. *Expert Opin Biol Ther*. 2018 Dec;18(12):1209-1221. doi: 10.1080/14712598.2018.1544240. (First name)
- Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma. *Front Immunol*. 2018; 9: 2749. doi: 10.3389/fimmu.2018.02749.
- Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A Consensus Paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. *J Intern Med*. 2019 Feb 6. doi: 10.1111/joim.12882.
- Lenalidomide-Based Induction And Maintenance In Elderly Newly Diagnosed Multiple Myeloma Patients: Updated Results Of The EMN01 Randomized Trial. *Haematologica*. 2019 Oct 3. doi: 10.3324/haematol.2019.226407

H-index 7

Mattia D'Agostino